HRT FINANCIAL LP sold $49K of BJDX

HRT FINANCIAL LP sold 34,938 shares of Bluejay Diagnostics, Inc. (BJDX) at $1.40 on 2026-07-10.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jul 13, 2026, 7:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 13, 2026, 7:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BJDX
Neutral
medium confidence
Mentioned
$BJDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BJDXNeutralLow
01

Why it matters

The newest fact is the reported open-market sale by a 10% owner at a specified price and share count; it may influence short-term sentiment but does not change operating outlook based on the provided text.

02

Market read

Traders may monitor for follow-on insider activity or interpret the sale as mild negative sentiment, but there is no new fundamental catalyst in the text.

03

What to watch

No 10b5-1 plan is stated, but the article also lacks context on total holdings, prior sales cadence, or whether the sale was part of broader portfolio rebalancing.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-13, sale dated 2026-07-10

Background

This is an SEC Form 4 insider transaction disclosure for Bluejay Diagnostics, Inc. (BJDX).

Company-level read

Ticker impact

$BJDXNeutralMedium confidence
Context

HRT Financial LP, a 10% owner, filed a Form 4 selling 34,938 BJDX shares at $1.40 on 2026-07-10.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven.

Evidence & confidence

The filing is a routine insider sale with no 10b5-1 plan and no accompanying company-specific news (earnings, guidance, trials, deals). Size is moderate, so impact is usually contained.

Market effects

No sector read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The sale may be liquidity-driven and not a bearish signal, especially since the filing provides no rationale or linkage to company performance.

Key entities

  • Bluejay Diagnostics, Inc.

    Subject of the Form 4 insider sale disclosure (BJDX).

  • HRT Financial LP

    10% owner who sold 34,938 shares in an open-market transaction.

  • SEC Form 4

    Primary-source insider transaction report filed on 2026-07-13.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BJDXMed

Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update Completes SYMON-II clinical study enrollment and advances clinical validation activities Achieves critical manufacturing milestone ahead of contractual deadline, strengtheni

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 For Immediate Release Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock. SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Towar

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics (NASDAQ:BJDX) announced baseline clinical data from its SYMON-II study, evaluating IL-6 as a biomarker for 28-day mortality risk in sepsis patients. The study included 777 patients, with an 18% mortality rate. The company aims to use this data to support a regulatory submission for its Symphony IL-6 Test, which is not yet FDA-approved.